Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate to severe plaque psoriasis, it was reported yesterday.
The phase 3 trial, called ECLIPSE, enrolled 1,048 patients to assess the efficacy and safety of Tremfya in comparison to Cosentyx. Tremfya is an interleukin (IL)-23-targeted biologic therapy and Cosentyx is an IL-17 inhibitor owned by Novartis.
The company revealed that 84.5% of patients, who were subjected to Tremfya, had indicated an improvement of around 90% in their baseline Psoriasis Area Severity Index (PASI) score at week 48. This was in comparison to 70% of patients on treatment with Cosentyx.
Tremfya is approved in the US and Europe or the treatment of adults with moderate to severe plaque psoriasis.
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
Champions Oncology expands bioanalytical services with new technology and leadership
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
Poolbeg Pharma trial to feature in major CRS research programme
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Proteome Sciences wins third US biopharma contract for new clinical assay
Lundbeck reports results from long-term follow-up of epilepsy patients treated with bexicaserin
CARsgen Therapeutics presents CT0596 study data at 2005 ASH Annual Meeting
AsymBio starts commercial production at Shanghai Fengxian Manufacturing Base
Innovent Biologics and Takeda sign global strategic partnership